Synuclein dementias (including dementia with Lewy bodies and Parkinson’s disease dementia)
Our research theme uses cutting-edge genetic and biomarker technology for advancement in medication and diagnostic tools for dementia with Lewy bodies (DLB), Parkinson’s disease dementia (PDD) and other synuclein related dementias.
The overarching aims are to enable pre-clinical diagnosis for these dementias, improve symptomatic treatments and develop disease modifying medicines.
Theme Lead: Professor Clive Ballard
- Validate neuroimaging and cerebrospinal fluid biomarkers for the pre-clinical diagnosis of dementia with DLB and PDD.
- Identify clinical, genetic and biomarker predictors of treatment response and adverse effects to cognitive and neuropsychiatric medicines.
- Conduct first-in-man clinical trials of more effective symptomatic and disease modifying therapies for synuclein dementias and those at risk of developing synuclein dementias including novel pharmacological approaches, cellular therapy and exercise.